2013 Director compensation narrative

Annual Retainer: In 2013, non-management directors received an annual retainer of $250,000. Chairs of the Directors and Corporate Governance Committee and the Executive Compensation and Management Resources Committee received an additional annual retainer of $20,000, and the chair of the Audit Committee received an additional annual retainer of $25,000. Effective May 1, 2014, the Presiding Director will receive an additional annual retainer of $15,000.

Under the IBM Deferred Compensation and Equity Award Plan (DCEAP), amended and restated effective January 1, 2014, 60% of the total annual retainer is required to be deferred and paid in Promised Fee Shares (PFS). Each PFS is equal in value to one share of the Company's common stock. When a cash dividend is paid on the Company's common stock, each director's PFS account is credited with additional PFS reflecting a dividend equivalent payment. With respect to the payment of the remaining 40% of the annual retainer, directors may elect one or any combination of the following: (a) deferral into PFS, (b) deferral into an interest-bearing cash account, and/or (c) receipt of cash payments on a quarterly basis during service as a Board member. The Company does not pay above-market or preferential earnings on compensation deferred by directors. Under the IBM Board Corporate Governance Guidelines, within five years of initial election to the Board, non-management directors are expected to have stock-based holdings in IBM equal in value to five times the annual retainer initially payable to such director. Stock-based holdings mean (i) IBM shares owned personally or by members of the immediate family sharing the same household and (ii) DCEAP PFS. Stock-based holdings do not include unexercised options.

Payout under the DCEAP: Upon a director's retirement or other completion of service as a director (a) all amounts deferred as PFS are payable, at the director's choice, in either cash and/or shares of the Company's common stock, and (b) amounts deferred into the interest-bearing cash account are payable in cash. Payouts may be made in either (a) a lump sum payment as soon as practicable after the date on which the director ceases to be a member of the Board, (b) a lump sum payment paid in February of the calendar year immediately following the calendar year in which the director ceases to be a member of the Board, or (c) between two and ten annual installments, each paid beginning in February following the calendar year in which the director ceases to be a member of the Board. If a director elects to receive PFS in cash, the payout of PFS is valued using the closing price of IBM common stock on the New York Stock Exchange as follows: for payouts made in an immediate lump sum, IBM stock will be valued on the date on which the director ceases to be a member of the Board and for lump sum payments made in February of the calendar year immediately following the calendar year of separation or for installment payouts, IBM stock will be valued on the last business day of the January preceding such February payment.

Termination of IBM Non-Employee Directors Stock Option Plan (DSOP): Prior to January 1, 2007, non-management directors who had been elected or reelected as a member of the Board as of the adjournment of the Annual Meeting of Stockholders received, on the first day of the month following such meeting, an annual grant of options to purchase 4,000 shares of IBM common stock. The exercise price of the options was the average of the high and low sales prices of IBM common stock on the New York Stock Exchange on the date of grant. Each option has a term of ten years and became exercisable in four equal installments commencing on the first anniversary of the date of grant and continuing for the three successive anniversaries thereafter. All options granted under the DSOP have vested. Effective January 1, 2007, the DSOP was terminated. Therefore, the 2013 Director Compensation Table does not include any option awards. However, the table below entitled "Aggregate Number of Option Awards Outstanding for Each Director at Fiscal Year-End" reflects any options outstanding under the DSOP as of year end 2013.

IBM's Matching Grants Program: Non-management directors are eligible to participate in the Company's Matching Grants Program on the same basis as the Company's employees based in the United States. Under this program, the Company will provide specified matches in cash or equipment in connection with a director's eligible contributions to approved educational institutions, medical facilities, and cultural or environmental institutions. The Company matches eligible contributions in cash on a 1-to-1 basis and in equipment on a 2-to-1 basis. Each director is eligible for a Company match on total gifts up to $10,000 per calendar year. Amounts shown in the 2013 Director Compensation Table for matching grants may be in excess of $10,000 because such amounts include Company contributions on gifts that were made by directors in previous years.

2013 Director compensation table

Fees Earned or Paid in Cash (column (b)): Amounts shown in this column reflect the annual retainer paid to each director as described above. A director receives a pro-rated amount of the annual retainer for service on the Board and, if applicable, as Presiding Director or a committee chair, based on the portion of the year the director served.

All Other Compensation (column (c)): Amounts shown in this column represent:

Name
(a)
Fees Earned or Paid in Cash ($)
(b)
All Other Compensation($) (1)
(c)
Total($)
(d)
A.J.P. Belda $250,000 $37,262 $287,262
W.R. Brody 250,000 49,309 299,309
K.I. Chenault 250,000 72,921 322,921
M.L. Eskew 275,000 57,971 332,971
D.N. Farr 250,000 19,007 269,007
S.A. Jackson 250,000 50,285 300,285
A.N. Liveris 250,000 18,243 268,243
W.J. McNerney, Jr. 250,000 40,752 290,752
J.W. Owens 250,000 48,308 298,308
J.E. Spero 250,000 74,862 324,862
S. Taurel 270,000 75,002 345,002
L.H. Zambrano 270,000 60,040 330,040

(1) Amounts in this column include the following: for Mr. Belda: $32,146 of dividend equivalent payments on PFS; for Dr. Brody: $39,194 of dividend equivalent payments on PFS and $10,000 contributed by the Company under the Matching Grants Program; for Mr. Chenault: $72,806 of dividend equivalent payments on PFS; for Mr. Eskew: $56,355 of dividend equivalent payments on PFS; for Mr. Farr: $3,891 of dividend equivalent payments on PFS and $15,000 contributed by the Company under the Matching Grants Program; for Dr. Jackson: $50,169 of dividend equivalent payments on PFS; for Mr. Liveris: $18,127 of dividend equivalent payments on PFS; for Mr. McNerney: $20,636 of dividend equivalent payments on PFS and $20,000 contributed by the Company under the Matching Grants Program; for Mr. Owens: $43,192 of dividend equivalent payments on PFS; for Ms. Spero: $57,247 of dividend equivalent payments on PFS and $17,500 contributed by the Company under the Matching Grants Program; for Mr. Taurel: $69,887 of dividend equivalent payments on PFS; and for Mr. Zambrano: $59,924 of dividend equivalent payments on PFS.

Aggregate number of option awards outstanding for each director at fiscal year-end

As described above, until the termination of the DSOP effective January 1, 2007, non-management directors received an annual grant of options to purchase 4,000 shares of IBM common stock. All options in the following table are fully exercisable. Because Dr. Brody and Messrs. Belda, Farr, Liveris and McNerney joined the Board after the termination of the DSOP, they did not receive any options and therefore are not included in the following table. In addition, Dr. Jackson had no options outstanding at the end of 2013; therefore, she is not included in the table.

Director Option awards
K.I. Chenault 12,000
M.L. Eskew 8,000
J.W. Owens 4,000
J.E. Spero 12,000
S. Taurel 12,000
L.H. Zambrano 12,000

(This information reflects the 2014 Proxy Statement.)

Investor relations search

Learn about IBM

Help and feedback

Investor relations subscriptions